Abstract:Cisplatin has been used to treat various types of cancers for over 30 years, however, a number of serious side-effects of cisplatin have stimulated the quest for other metal-based anticancer agents. Iridium complexes are generally thought to be too inert to possess high reactivity, and therefore, there are only a few previous reports of the antitumour activity of iridium complexes. In this thesis a wide range of organometallic IrIII cyclopentadienyl complexes of the type [(η5-Cpx)Ir(XY)Cl]0/+ (where Cpx = pentamethylcyclopentadienyl (Cp*), tetramethyl(phenyl)cyclopentadienyl (Cpxph) or tetramethyl(biphenyl)cyclopentadienyl (Cpxbiph), XY = N,N-, N,O- or C^N-chelating ligand) has been synthesised and characterised. All the complexes hydrolyse rapidly in aqueous solution. Complexes with N,N-chelating ligands readily form adducts with 9-ethylguanine but not 9-ethyladenine; C^N- or N,O-chelated complexes bind to both purines. Guanine residues are preferential binding sites for 1,10-phenanthroline complexes on plasmid DNA. Replacement of the neutral N,N-bound chelating ligand by the negatively-charged C,N-bound analogues can improve biological activity. In addition, cytotoxic potency towards A2780 human ovarian cancer cells increases with phenyl substitution on Cp*: Cpxbiph > Cpxph > Cp*. This can be rationalised by increased hydrophobicity with more extended phenyl ring, resulting in increased cellular uptake and increased intercalative ability. Notably, several complexes exhibited submicromolar anticancer activity. The interconversion of 1,4-NADH and NAD+ through hydride-transfer reactions in the presence of cyclopentadienyl IrIII aqua complexes was studied. It is shown that the IrIII aqua complexes not only converts NAD+ to 1,4-NADH using formate as the hydride source, but can also catalyse the reverse reaction with hydride donation from 1,4-NADH to a iridium centre, recovered by protonation of bound hydride with generation of H2. This work demonstrates how the aqueous chemistry, nucleobase binding and anticancer activity of the IrIII cyclopentadienyl complexes can be controlled and fine-tuned by the modification of the chelating and cyclopentadienyl ligands. The results suggest that this new class of organometalic Ir(III) complexes is well suited for development as anticancer agents.

Design, synthesis, and evaluation of phosphorescent Ir(III) complexes with anticancer activity.

Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Lysosome-Targeted Phosphine-Imine Half-Sandwich Iridium(III) Anticancer Complexes: Synthesis, Characterization, and Biological Activity

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

Phosphorescent Iridium(III) Complexes for Anticancer Applications

Design and anticancer behaviour of cationic/neutral half-sandwich iridium(III) imidazole-phenanthroline/phenanthrene complexes

Design and Anticancer Behaviour of Cationic/neutral Half-Sandwich Iridium (III) Imidazole-Phenanthroline/phenanthrene Complexes

Synthesis and Antineoplastic Applications of TPE Appended Organometallic Iridium(III) Complexes.

Lysosome-Targeted Cyclometalated Iridium (Iii) Anticancer Complexes Bearing Phosphine-Sulfonate Ligands

Novel Lysosome-Targeted Cyclometalated Iridium(III) Anticancer Complexes Containing Imine-N-heterocyclic Carbene Ligands: Synthesis, Spectroscopic Properties and Biological Activity

Triphenylamine and carbazole‐modified iridiumIII 2‐phenylpyridine complexes: Synthesis, anticaner application and targeted research

Antitumor Activity and Application of Luminescent Iridium (III) Complexes

Fluorescent Half-Sandwich Phosphine-Sulfonate Iridium(iii) and Ruthenium(ii) Complexes As Potential Lysosome-Targeted Anticancer Agents

Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria

DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes

Organometallic Iridium Anticancer Complexes

Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells

Highly Potent Half- Sandwich Iridium and Ruthenium Complexes As Lysosome- Targeted Imaging and Anticancer Agents

Towards efficient Ir(iii) anticancer photodynamic therapy agents by extending π-conjugation on N^N ligands

Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis